Australian company Adherium (ASX: ADR) has announced the appointment of Geoff Feakes as its chief technology officer (CTO).
Mr Feakes will lead the company's R&D and innovation teams. Adherium is focused on digital inhaled device adherence, remote monitoring and data management solutions.
“I am pleased to announce Geoff’s appointment as CTO. Geoff brings 25 years’ experience in innovative information and data management along with experience in delivering commercial connected device technologies and telehealth across multiple international markets," said CEO Mike Motion.
"Geoff’s appointment marks an important step as we progress our R&D device and software platform development with Planet Innovation in Melbourne and further strengthens Adherium’s executive leadership team.”
The appointment follows the recent announcement of a $5 million investment by BioScience Managers Translation Fund 1 to support the development of its sensor device portfolio and software platform.
“I am delighted to take on the role of CTO and be part of the team that executes our strategy that will improve patients’ lives and deliver shareholder value,” said Mr Feakes.
“The relevance and adoption of telehealth and remote patient monitoring has been accelerated by COVID-19 and its role in managing vulnerable patients in healthcare systems.”
“Alongside reimbursement systems now in place in the USA for remote patient monitoring and telehealth Adherium is in a strong position to execute its focused provider and payer strategy.
"Adherium has a robust technology that provides a foundation upon which I intend to build, bringing into the Company my international experience in developing commercially focused connected integrated solutions across a number of therapeutic areas.
"I am looking forward to leading our team in partnership with Planet Innovation with a clear development roadmap in inhaled medication device coverage including physiological data reporting,” added Mr Feakes.